Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.

Ruben J ColmanYe XiongTomoyuki Mizuno Jeffrey S HyamsJoshua D NoeBrendan BoyleGeert R D'HaensJohan E Van LimbergenKelly ChunJane YangMichael J Rosen Lee A Denson Alexander A Vinks Phillip Paul Minar

Published in: Alimentary pharmacology & therapeutics (2021)

In this real-world cohort, ATI as low as 23 ng/mL impacted drug clearance. Our data suggest that dose optimisation for low-level ATI can improve infliximab clearance and prevent loss of response.

Keyphrases

intensive care unit
ulcerative colitis
emergency department
electronic health record
big data
artificial intelligence
drug induced